Takumi Endo

469 total citations
38 papers, 347 citations indexed

About

Takumi Endo is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Takumi Endo has authored 38 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 11 papers in Surgery and 10 papers in Oncology. Recurrent topics in Takumi Endo's work include Prostate Cancer Diagnosis and Treatment (9 papers), Prostate Cancer Treatment and Research (9 papers) and Bone health and treatments (6 papers). Takumi Endo is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (9 papers), Prostate Cancer Treatment and Research (9 papers) and Bone health and treatments (6 papers). Takumi Endo collaborates with scholars based in Japan and United States. Takumi Endo's co-authors include Hiroyoshi Suzuki, Naoto Kamiya, Masashi Yano, Tomohiko Ichikawa, Takashi Imamoto, Koji Kawamura, Takanobu Utsumi, Makoto Takano, Yukio Naya and Nobuyuki Sekita and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The Journal of Urology.

In The Last Decade

Takumi Endo

30 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takumi Endo Japan 11 133 126 97 77 73 38 347
Harry Nísen Finland 12 178 1.3× 115 0.9× 76 0.8× 196 2.5× 88 1.2× 40 450
Tına Mistry United Kingdom 6 61 0.5× 58 0.5× 106 1.1× 80 1.0× 27 0.4× 9 392
W. Cooper Buschemeyer United States 7 160 1.2× 47 0.4× 94 1.0× 100 1.3× 45 0.6× 10 402
Virendra Patil India 11 46 0.3× 152 1.2× 92 0.9× 64 0.8× 183 2.5× 60 395
Ching‐Chia Li Taiwan 13 139 1.0× 159 1.3× 64 0.7× 100 1.3× 49 0.7× 30 376
Donglei Zhou China 14 113 0.8× 146 1.2× 45 0.5× 140 1.8× 44 0.6× 29 418
Roberto L. Müller United States 9 241 1.8× 56 0.4× 67 0.7× 76 1.0× 121 1.7× 25 372
Anusila Deka United States 6 180 1.4× 56 0.4× 317 3.3× 163 2.1× 69 0.9× 6 525
Anne Pike United States 6 73 0.5× 119 0.9× 31 0.3× 44 0.6× 115 1.6× 8 395
Toshihisa Tomoda Japan 11 94 0.7× 99 0.8× 91 0.9× 66 0.9× 33 0.5× 38 310

Countries citing papers authored by Takumi Endo

Since Specialization
Citations

This map shows the geographic impact of Takumi Endo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takumi Endo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takumi Endo more than expected).

Fields of papers citing papers by Takumi Endo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takumi Endo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takumi Endo. The network helps show where Takumi Endo may publish in the future.

Co-authorship network of co-authors of Takumi Endo

This figure shows the co-authorship network connecting the top 25 collaborators of Takumi Endo. A scholar is included among the top collaborators of Takumi Endo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takumi Endo. Takumi Endo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ikeda, Ryusuke, et al.. (2025). Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Precision Immuno-Oncology. Cancers. 17(20). 3367–3367. 1 indexed citations
2.
Suzuki, Yuta, et al.. (2025). Impact of the COVID ‐19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns. International Journal of Urology. 32(8). 990–996. 2 indexed citations
5.
Kamiya, Naoto, Taro Okazaki, Yuta Suzuki, et al.. (2025). Multidisciplinary Treatment for Lymphorrhea and Chylorrhea Following Lymph Node Dissection for Genitourinary Cancer. Cancers. 17(4). 592–592.
6.
Suzuki, Yuta, et al.. (2025). Development, Validation, and Clinical Utility of a Nomogram for Urological Tumors: How to Build the Best Predictive Model. International Journal of Urology. 32(8). 919–931. 3 indexed citations
9.
Watanabe, Takuya, et al.. (2024). The utility of the low motion area ratio for the preoperative detection of pleural adhesions: dynamic chest radiography analysis. Quantitative Imaging in Medicine and Surgery. 15(1). 843–851.
10.
Saga, Norihiko, et al.. (2018). Development of peristaltic crawling robot which imitates muscle structure of an earthworm. SHILAP Revista de lepidopterología. 84(861). 17–548. 1 indexed citations
11.
Endo, Takumi, et al.. (2018). TRANSITION OF FORM OF ARCHITECTURAL FAÇADE IN RECENT YEARS. AIJ Journal of Technology and Design. 24(58). 1173–1178. 2 indexed citations
12.
Utsumi, Takanobu, Naoto Kamiya, Takumi Endo, et al.. (2017). Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism. World Journal of Urology. 35(10). 1577–1583. 16 indexed citations
13.
Utsumi, Takanobu, Takumi Endo, Masashi Yano, et al.. (2016). Clinical predictors for high-grade bladder cancer before first-time transurethral resection of the bladder tumor: a retrospective cohort study. Japanese Journal of Clinical Oncology. 46(10). 964–967. 9 indexed citations
14.
Suzuki, Hiroyoshi, Takanobu Utsumi, Takumi Endo, et al.. (2016). Abiraterone acetate as first-line treatment for CRPC. Annals of Oncology. 27. vii54–vii54. 1 indexed citations
15.
Utsumi, Takanobu, Takumi Endo, Masashi Yano, et al.. (2015). Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. International Journal of Clinical Oncology. 21(2). 389–396. 21 indexed citations
16.
Usuda, Haruki, Takumi Endo, Makoto Tominaga, et al.. (2012). Transient Receptor Potential Vanilloid 1 — a Polymodal Nociceptive Receptor — Plays a Crucial Role in Formaldehyde-Induced Skin Inflammation in Mice. Journal of Pharmacological Sciences. 118(2). 266–274. 10 indexed citations
17.
Kamiya, Naoto, Hiroyoshi Suzuki, Takumi Endo, et al.. (2012). Clinical usefulness of bone markers in prostate cancer with bone metastasis. International Journal of Urology. 19(11). 968–979. 29 indexed citations
18.
Kamiya, Naoto, Hiroyoshi Suzuki, Takumi Endo, et al.. (2011). Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. International Journal of Urology. 19(2). 169–173. 15 indexed citations
19.
Kamiya, Naoto, Hiroyoshi Suzuki, Takumi Endo, et al.. (2011). Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. International Journal of Clinical Oncology. 16(4). 366–372. 15 indexed citations
20.
Kamiya, Naoto, Hiroyoshi Suzuki, Masashi Yano, et al.. (2010). Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis. Urology. 75(6). 1446–1451. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026